<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="bf748572-feba-4465-99e0-234e04a63cfc"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <br/>These highlights do not include all the information needed to use ENCELTO™ safely and effectively. See full prescribing information for ENCELTO.<br/>
      <br/>ENCELTO (revakinagene taroretcel-lwey) implant, for intravitreal use<br/>Initial U.S. Approval: 2025</title>
   <effectiveTime value="20250321"/>
   <setId root="1ae9482a-b478-4e21-9166-b5fd52d3ef9c"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117685116"/>
            <name>Neurotech Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f7051294-8554-4d0e-ae29-043eee8fdcf6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <title/>
               <text/>
               <effectiveTime value="20250317"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="82958-501" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ENCELTO</name>
                        <formCode code="C42942" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="IMPLANT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>revakinagene taroretcel-lwey</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="440000" unit="[arb'U]"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q7V7NYG6GM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>REVAKINAGENE TARORETCEL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q7V7NYG6GM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>REVAKINAGENE TARORETCEL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C92708" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82958-501-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43186" displayName="CONTAINER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250312"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102838" displayName="Type 5: Device Coated or Otherwise Combined with Biologic" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250312"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA125798" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="capsule" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38280" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVITREAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L334997e9-7e44-40ed-9f45-264f518fddeb">
               <id root="253396a5-c427-4e1b-bb07-e75d91d75e07"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ENCELTO is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).</paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ENCELTO is an allogeneic encapsulated cell-based gene therapy indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L53ec129a-d02f-4fe3-8800-c10ab1abddcd">
               <id root="53c80221-cf01-4d31-affa-5f498bdbac5d"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph styleCode="First PIHLBulletText">
                           <content styleCode="bold">For intravitreal implantation only. </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>ENCELTO is intended for surgical intravitreal implantation under aseptic conditions by a qualified ophthalmologist. (<linkHtml href="#Lb8f54b19-6d78-414b-a534-812148fda5b6">2.1</linkHtml>)</item>
                           <item>The recommended dose is one ENCELTO implant per affected eye containing 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotrophic factor (rhCNTF). (<linkHtml href="#Lb8f54b19-6d78-414b-a534-812148fda5b6">2.1</linkHtml>)</item>
                           <item>Carefully inspect ENCELTO prior to use and refer to the Instructions for Use when preparing for and performing surgical placement or removal of ENCELTO. (<linkHtml href="#L6f9de807-cc23-4e19-8ff0-a887b3a03c8b">2.2</linkHtml>, <linkHtml href="#L376b762e-8e65-4fe9-a39c-392a1888f6f1">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Lb8f54b19-6d78-414b-a534-812148fda5b6">
                     <id root="a2f4748f-1697-4182-942f-4cdadc8b65f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dose</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">For intravitreal implantation only</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>• ENCELTO is administered by a single surgical intravitreal procedure performed by a qualified ophthalmologist.</paragraph>
                        <paragraph>• The recommended dose is one ENCELTO implant per affected eye. Each ENCELTO implant contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotrophic factor (rhCNTF) (NTC-201-6A cell line), a neurotrophic factor.</paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="L6f9de807-cc23-4e19-8ff0-a887b3a03c8b">
                     <id root="1663a5ba-e0d2-4200-96ed-7b6c25fe443f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 ENCELTO Surgical Placement</title>
                     <text>
                        <paragraph>The ENCELTO implant insertion is a surgical procedure performed in an operating room under aseptic conditions by a qualified ophthalmologist. </paragraph>
                        <paragraph/>
                        <table>
                           <caption/>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Pre-Surgical Preparation</content>
                                    </paragraph>
                                    <list listType="ordered">
                                       <item>Inspect the ENCELTO packaging for any signs of damage or leakage.</item>
                                       <item>Verify the use-by date.</item>
                                       <item>Confirm that the disposable temperature recording device displays a checkmark at the top of the screen.</item>
                                       <item>Ensure the liquid medium is at the correct pH using the provided pH color guide reference card.</item>
                                    </list>
                                    <paragraph>Prepare the surgical field properly.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Surgical Steps</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">1. Preparing the Surgical Site</content>
                                    </paragraph>
                                    <paragraph>    a. Create a 7x7 mm peritomy of the conjunctiva and Tenon’s capsule at the selected implantation site.</paragraph>
                                    <paragraph>    b. Place a corneal-limbal traction suture in the selected surgical quadrant (either inferotemporal or inferonasal) (<linkHtml href="#figure1-2">Figure 1</linkHtml>).</paragraph>
                                    <paragraph>    c. Maintain hemostasis of the underlying sclera and conjunctiva (<linkHtml href="#figure1-2">Figure 1</linkHtml>).</paragraph>
                                    <paragraph>    d. Using an MVR and 15-degree blade, create a 3.0 mm full-thickness sclerotomy 3.75 mm posterior and parallel to the limbus (<linkHtml href="#figure1-2">Figure 2</linkHtml>). Do not insert ENCELTO outside of the pars plana.</paragraph>
                                    <paragraph>    e. Confirm:</paragraph>
                                    <paragraph>        • The incision is full thickness.</paragraph>
                                    <paragraph>        • There is adequate hemostasis.</paragraph>
                                    <paragraph>        • There is no spanning uveal tissue.</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="La96c16bf-a031-48da-bcda-b74fe49f5434" ID="figure1-2"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">2. Preparing the ENCELTO Implant</content>
                                    </paragraph>
                                    <paragraph>    a. Open the inner container and expose the upper compartment and luer lock cap (<linkHtml href="#figure3-4">Figure 3</linkHtml>).</paragraph>
                                    <paragraph>    b. Unlock the luer lock cap by turning it counterclockwise once.</paragraph>
                                    <paragraph>    c. Lift the luer lock cap vertically to remove ENCELTO (attached to the gripper).</paragraph>
                                    <paragraph>    d. Rinse ENCELTO with at least 5 mL of sterile Balanced Saline Solution (BSS).</paragraph>
                                    <paragraph>    e. Keep ENCELTO moist by applying BSS every 10 minutes until insertion.</paragraph>
                                    <paragraph>    f. While holding the luer lock cap, pass a double-armed 9-0 polypropylene suture needle through ENCELTO’s fixation loop (<linkHtml href="#figure3-4">Figure 4</linkHtml>).</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="L47dbb4b3-67e5-46a0-a0c4-f2bde686a0e8" ID="figure3-4"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">3. Implantation of ENCELTO</content>
                                    </paragraph>
                                    <paragraph>    a. Gently open the sclerotomy incision and insert ENCELTO perpendicularly into the eye (<linkHtml href="#figure5-6">Figure 5</linkHtml>).</paragraph>
                                    <paragraph>    b. Ensure only the fixation loop is exposed.</paragraph>
                                    <paragraph>    c. Release ENCELTO from the gripper by squeezing the indicated region with forceps or a fine needle holder (<linkHtml href="#figure5-6">Figure 6</linkHtml>).</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="L7f94b88f-15c2-4fd2-936f-5c422de8e36f" ID="figures5-6"/>
                                    </paragraph>
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">4. Securing the Implant</content>
                                    </paragraph>
                                    <paragraph>    a. Secure ENCELTO by creating a 3-1-1 anchor knot with the polypropylene suture at the apex of the fixation loop (<linkHtml href="#figure7-8">Figure 7</linkHtml>).</paragraph>
                                    <paragraph>    b. Confirm ENCELTO is centered in the incision.</paragraph>
                                    <paragraph>    c. Pass each suture arm centrally through either side of the wound at 90-99% scleral depth (<linkHtml href="#figure7-8">Figure 8</linkHtml>).</paragraph>
                                    <paragraph>    d. Pull up the suture ends and confirm that the fixation loop is at the proper depth (90-99%).</paragraph>
                                    <paragraph>    e. Tie down the suture to the sclera with a 3-1-1 knot, ensuring the knot is placed away from the incision.</paragraph>
                                    <paragraph>    f.  If a suture breaks, leave the tail as long as possible and lay it flat.</paragraph>
                                    <paragraph>    g. Take a 2.0 mm scleral bite at 50-75% depth beyond the sclerotomy on each side (<linkHtml href="#figure7-8">Figure 9</linkHtml>).</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="L62f66819-cf1a-418d-bc6d-683500c4e7ac" ID="figures7-8"/>
                                    </paragraph>
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">5. Closing the Incision</content>
                                    </paragraph>
                                    <paragraph>    a. Close the scleral incision with 9-0 nylon sutures (<linkHtml href="#figure10">Figure 10</linkHtml>), ensuring:</paragraph>
                                    <list listType="unordered">
                                       <item>The polypropylene suture is captured to prevent irritation and erosion.</item>
                                       <item>All nylon suture knots are rotated into the sclera.</item>
                                       <item>The closure is watertight.</item>
                                    </list>
                                    <paragraph>    b. Pull the polypropylene suture end taut and cut it flush to the sclera.</paragraph>
                                    <paragraph>    c. Close the conjunctiva and Tenon’s capsule using 6-0 plain gut or chromic suture, or 7-0 Vicryl suture or similar.</paragraph>
                                    <paragraph>    d. Ensure Tenon’s capsule covers the insertion site and use 3-point fixation and scleral bites.</paragraph>
                                    <paragraph>    e. Administer sub-conjunctival steroid injection: dexamethasone, 2 mg/0.5 ml (4 mg/ml) or equivalent. If the case is complicated and inflammation is anticipated, a higher dose of dexamethasone (0.5 cc of 10 mg/ml) or equivalent may be used, at the surgeon’s discretion.</paragraph>
                                    <paragraph>    f. Perform indirect ophthalmoscopy to confirm placement of ENCELTO in the vitreous and that there are no intraocular complications. Failure to perform indirect ophthalmoscopy can lead to unidentified malpositioning of ENCELTO and intraocular complications.</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="L438e1ab3-a3c5-4fb3-a4e8-2d458fefe201" ID="figure10"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Post-Operative Wound Care</content>
                                    </paragraph>
                                    <list listType="unordered">
                                       <item>The patient is to use:<list listType="unordered">
                                             <item>A topical antibiotic solution at a frequency of 1 drop four times a day for 7 days.</item>
                                             <item>A steroid drop taper of prednisolone acetate 1% (or equivalent) starting the day after surgery with the following taper:<list listType="unordered">
                                                   <item>1 drop four times a day for the first 7 days;</item>
                                                   <item>1 drop three times a day for the next 7 days;</item>
                                                   <item>1 drop two times a day for the next 7 days;</item>
                                                   <item>1 drop once a day for the last 7 days.</item>
                                                </list>
                                             </item>
                                          </list>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Refer to ENCELTO Instructions for Use for detailed guidance on implantation procedure.</paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                     <component>
                        <observationMedia ID="La96c16bf-a031-48da-bcda-b74fe49f5434">
                           <text>figures 1 and 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L47dbb4b3-67e5-46a0-a0c4-f2bde686a0e8">
                           <text>figures 3 and 4</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L7f94b88f-15c2-4fd2-936f-5c422de8e36f">
                           <text>figures 5 and 6</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L62f66819-cf1a-418d-bc6d-683500c4e7ac">
                           <text>figures 7-9</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L438e1ab3-a3c5-4fb3-a4e8-2d458fefe201">
                           <text>figure 10</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-5.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="L376b762e-8e65-4fe9-a39c-392a1888f6f1">
                     <id root="b6036022-8af4-4c53-8c44-8b12b1f396eb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 ENCELTO Removal Procedure</title>
                     <text>
                        <paragraph>Removal of ENCELTO is a surgical procedure performed in an operating room under aseptic conditions by a qualified ophthalmologist. Remove ENCELTO implant, if vitrectomy with a complete gas fill or silicone oil fill is required or if infectious endophthalmitis occurs.</paragraph>
                        <table>
                           <caption/>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Surgical Steps</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">1. Preparing the Surgical Site (<linkHtml href="#figure11">Figure 11</linkHtml>)</content>
                                    </paragraph>
                                    <paragraph>    a. Create a 7x7 mm peritomy of the conjunctiva and Tenon’s capsule to expose the insertion site.</paragraph>
                                    <paragraph>    b. <content>Place a corneal-limbal traction suture in the quadrant where ENCELTO is located.</content>
                                    </paragraph>
                                    <paragraph>    c. Maintain hemostasis of the sclera and surrounding conjunctiva.</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="Le8d582e4-c339-4e77-9c47-afe6951a3c0b" ID="figure11"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">2. Establishing Infusion &amp; Vitrectomy (<linkHtml href="#figure12">Figure 12</linkHtml>)</content>
                                    </paragraph>
                                    <paragraph>    a. Place an infusion cannula in the inferior quadrant (opposite ENCELTO).</paragraph>
                                    <paragraph>    b. Confirm the infusion line is positioned within the vitreous cavity before opening the infusion.</paragraph>
                                    <paragraph>    c. Insert two superior cannulas following normal pars plana vitrectomy protocol.</paragraph>
                                    <paragraph>    d. Perform a thorough vitrectomy to remove vitreous surrounding ENCELTO without disrupting the hollow fiber membrane.</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="L2cf01f67-fbc7-4f92-9fec-d13f549b1775" ID="figure12"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">3. Reopening the Sclerotomy</content>
                                    </paragraph>
                                    <paragraph>    a. Locate the ENCELTO incision and remove the two nylon sutures while leaving the polypropylene suture intact (<linkHtml href="#figure13-14">Figure 13</linkHtml>).</paragraph>
                                    <paragraph>    b. Using an MVR blade, carefully dissect open the original scleral incision down to the ENCELTO cap at the base of the fixation loop (<linkHtml href="#figure13-14">Figure 14</linkHtml>).</paragraph>
                                    <paragraph>    c. Extend the incision along the entire 3.0 mm length to full thickness.</paragraph>
                                    <paragraph>    d. Cut the polypropylene anchor suture on the anterior side of the knot.</paragraph>
                                    <paragraph>    e. Turn off or lower infusion pressure.</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="L84e24c85-224e-47d6-a2f8-106f91b38783" ID="figure13-14"/>
                                    </paragraph>
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">4. Removing ENCELTO (<linkHtml href="#figure15">Figure 15</linkHtml>)</content>
                                    </paragraph>
                                    <paragraph>    a. Fully open the pars plana sclerotomy and confirm there is no spanning uveal tissue.</paragraph>
                                    <paragraph>    b. <content>Identify and grasp the fixation loop.</content>
                                    </paragraph>
                                    <paragraph>    c. Cut off the remaining polypropylene knot.</paragraph>
                                    <paragraph>    d. Remove ENCELTO from the eye.</paragraph>
                                    <paragraph>    e. Inspect the ENCELTO capsule for any damage or penetration.</paragraph>
                                    <paragraph>    f. Do not discard or dispose of the ENCELTO implant. Call and report to 1-833-963-9275. The appropriate action will be taken to initiate the return of ENCELTO and possible replacement.</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="Lb37d53f8-d735-4cee-be7d-0d2e874bd3ff" ID="figure15"/>
                                    </paragraph>
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">5. Closing the Incision</content>
                                    </paragraph>
                                    <paragraph>    a. Remove any prolapsed vitreous.</paragraph>
                                    <paragraph>    b. Close the sclerotomy with interrupted 7-0 Vicryl sutures for a watertight closure.</paragraph>
                                    <paragraph>    c. Remove the infusion line and additional cannulas.</paragraph>
                                    <paragraph>    d. Close the conjunctiva with 6-0 plain gut sutures or equivalent.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Post-Operative Wound Care</content>
                                    </paragraph>
                                    <list listType="unordered">
                                       <item>The patient is to use:<list listType="unordered">
                                             <item>A topical antibiotic solution at a frequency of 1 drop four times a day for 7 days.</item>
                                             <item>A steroid drop taper of prednisolone acetate 1% (or equivalent) starting the day after surgery with the following taper:<list listType="unordered">
                                                   <item>1 drop four times a day for the first 7 days;</item>
                                                   <item>1 drop three times a day for the next 7 days;</item>
                                                   <item>1 drop two times a day for the next 7 days;</item>
                                                   <item>1 drop once a day for the last 7 days.</item>
                                                </list>
                                             </item>
                                          </list>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Refer to ENCELTO Instructions for Use for detailed guidance on removal procedure.</paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                     <component>
                        <observationMedia ID="Le8d582e4-c339-4e77-9c47-afe6951a3c0b">
                           <text>Figure 11</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-6.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L2cf01f67-fbc7-4f92-9fec-d13f549b1775">
                           <text>Figure 12</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-7.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L84e24c85-224e-47d6-a2f8-106f91b38783">
                           <text>Figures 13 and 14</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-8.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Lb37d53f8-d735-4cee-be7d-0d2e874bd3ff">
                           <text>Figure 15</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-9.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Le648d87d-aba9-4ba9-87cf-39d655d96673">
               <id root="b19cdace-ce57-4789-8205-156fba82d992"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>ENCELTO is a single-dose implant that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotrophic factor (rhCNTF) (NTC-201-6A cell line) for intravitreal surgical placement. ENCELTO is an opaque semi-permeable capsule that is white to off-white, capped on both ends, and has a titanium loop on one end. The ENCELTO width is 1.2 ± 0.1 mm, its length is 6.1 ± 0.4 mm, and its internal diameter is 0.88 ± 0.02 mm (<linkHtml href="#figure17">Figure 17</linkHtml>).</paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One single-dose implant containing 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing rhCNTF. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="La814e0a9-0f55-4dff-ad48-27bd4034dae9">
               <id root="1b667c18-2cd3-4be3-8130-7358e18cfdda"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ENCELTO is contraindicated in patients with: <content styleCode="bold"/>
                  </paragraph>
                  <list listType="unordered">
                     <item>Active or suspected ocular or periocular infections.  </item>
                     <item>Known hypersensitivity to Endothelial Serum Free Media (Endo-SFM)</item>
                  </list>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Ocular or periocular infections. (<linkHtml href="#La814e0a9-0f55-4dff-ad48-27bd4034dae9">4</linkHtml>)</item>
                           <item>Known hypersensitivity to Endothelial Serum Free Media (Endo-SFM). (<linkHtml href="#La814e0a9-0f55-4dff-ad48-27bd4034dae9">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L45999af3-0a1e-4eaa-a6ae-f5af7425dc82">
               <id root="9d9509bd-2756-44f8-8e8d-6f69ffc198dd"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>ENCELTO implantation has been associated with severe vision loss, infectious endophthalmitis, retinal tears and/or detachment, vitreous hemorrhage, implant extrusion, cataract formation, suture related complications, and delayed dark adaptation. Patients should be instructed to report signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required. (<linkHtml href="#L4e266865-106c-4cec-9a21-4cf1059dfd41">5.1</linkHtml>, <linkHtml href="#Le45e9d6f-bb11-4526-b18f-87a4cb8c71c3">5.2</linkHtml>, <linkHtml href="#Lbd7e23ba-2015-4f91-97c2-95cd4aa9f1d9">5.3</linkHtml>, <linkHtml href="#L13b52b52-a81a-4952-805a-9bf3526b3426">5.4</linkHtml>, <linkHtml href="#L22c6eb21-d865-48cb-a4fc-0e86df020550">5.5</linkHtml>, <linkHtml href="#Lcc1cb866-8b01-4bb0-8749-1b7931639085">5.6</linkHtml>, <linkHtml href="#Lb64cbe3e-f57c-4ba1-b88a-6d7dbcb635b1">5.7</linkHtml>, <linkHtml href="#Lfef928a7-1089-440d-a5b5-7d2d27fbace1">5.8</linkHtml>)</item>
                        </list>
                        <list listType="unordered">
                           <item>Vitreous Hemorrhage: Temporarily discontinue antithrombotic medication prior to ENCELTO insertion surgery to reduce the risk of implantation related vitreous hemorrhage. Vitreous hemorrhages occurring greater than one year from implantation could be a sign of ENCELTO extrusion. The surgical site should be examined closely and the ENCELTO should be surgically repositioned if indicated. (<linkHtml href="#L13b52b52-a81a-4952-805a-9bf3526b3426">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L4e266865-106c-4cec-9a21-4cf1059dfd41">
                     <id root="acdcdd7b-4249-4dcc-be9a-e56d1ca83335"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Severe Vision Loss</title>
                     <text>
                        <paragraph>Severe vision loss defined as three or more lines of visual acuity loss [≥15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] has occurred following ENCELTO implantation [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6ccd7df0-0701-4c03-934b-03538ea16908">Adverse Reactions (6)</linkHtml>
                           </content>]. Monitor patients for signs and symptoms of vision loss and manage as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="Le45e9d6f-bb11-4526-b18f-87a4cb8c71c3">
                     <id root="d7fb4f2f-f084-46f4-b37c-1613c24652c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Infectious Endophthalmitis</title>
                     <text>
                        <paragraph>Infectious endophthalmitis may occur following ENCELTO implantation. Signs and symptoms of infectious endophthalmitis include progressively worsening eye pain, vision loss, or scleral and conjunctival injection. To mitigate the risk of endophthalmitis, use proper aseptic surgical technique for ENCELTO implantation [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6f9de807-cc23-4e19-8ff0-a887b3a03c8b">Dosage and Administration (2.2)</linkHtml>
                           </content>]. Monitor patients for signs or symptoms of infectious endophthalmitis. Remove ENCELTO implant if infectious endophthalmitis occurs and manage symptoms according to clinical practice.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Lbd7e23ba-2015-4f91-97c2-95cd4aa9f1d9">
                     <id root="b92956d9-6cd2-47c4-9186-5dbe81fd35e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Retinal Tear and Detachment</title>
                     <text>
                        <paragraph>Retinal tears and retinal detachment may occur following ENCELTO implantation. Signs and symptoms of retinal tears include acute onset of flashing lights, floaters, and/or loss of visual acuity. Signs and symptoms of retinal detachment may include progressive visual field loss and/or loss of visual acuity. Use standard vitreoretinal surgical techniques during ENCELTO implantation to minimize the risk of retinal tears and retinal detachment. Monitor for any signs or symptoms of retinal tear and/or retinal detachment. Treat rhegmatogenous retinal detachment and retinal tears promptly. Remove ENCELTO implant, if vitrectomy with a complete gas fill or silicone oil fill is required [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L376b762e-8e65-4fe9-a39c-392a1888f6f1">Dosage and Administration (2.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="L13b52b52-a81a-4952-805a-9bf3526b3426">
                     <id root="62a2ff28-a5a7-4aca-bc4c-64f6efa92fab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Vitreous Hemorrhage</title>
                     <text>
                        <paragraph>Vitreous hemorrhage, which may result in temporary vision loss, has occurred following ENCELTO implantation [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6ccd7df0-0701-4c03-934b-03538ea16908">Adverse Reactions (6)</linkHtml>
                           </content>]. Patients receiving antithrombotic medication (e.g., oral anticoagulants, aspirin, nonsteroidal anti-inflammatory drugs) may be at increased risk of vitreous hemorrhage. To reduce the risk of vitreous hemorrhage, interrupt antithrombotic medications prior to the ENCELTO implantation. Vitrectomy surgery may be necessary to clear severe, recurrent, or non-clearing vitreous hemorrhage. If the patient has a late onset vitreous hemorrhage (greater than one year following ENCELTO implantation surgery), examine the ENCELTO implantation site for possible implant extrusion. If implant extrusion has occurred, surgically reposition ENCELTO [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L22c6eb21-d865-48cb-a4fc-0e86df020550">Implant Extrusion (5.5)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="L22c6eb21-d865-48cb-a4fc-0e86df020550">
                     <id root="eaf107d8-f628-4d7b-8c15-27e9d205c926"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Implant Extrusion</title>
                     <text>
                        <paragraph>
                           <content>Implant extrusion through the initial scleral wound has occurred following ENCELTO implantation [<content styleCode="italics">see  </content>
                              <content styleCode="italics">
                                 <linkHtml href="#L6ccd7df0-0701-4c03-934b-03538ea16908">Adverse Reactions (6)</linkHtml>
                              </content>]. Signs and symptoms of implant extrusion include recurrent uveitis, vitreous hemorrhage, eye pain more than one year after implantation, or visibility of titanium fixation loop under the conjunctiva. To reduce the risk of implant extrusion, carefully follow the specific surgical steps for ENCELTO implantation [<content styleCode="italics">see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#L6f9de807-cc23-4e19-8ff0-a887b3a03c8b">Dosage and Administration (2.2)</linkHtml>
                              </content>].</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content>Evaluate patients after 6 months to confirm proper positioning of ENCELTO and then annually. If ENCELTO begins to extrude, surgically reposition ENCELTO to a proper scleral wound depth either in the same site or in the opposing inferior quadrant of the vitreous cavity.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Lcc1cb866-8b01-4bb0-8749-1b7931639085">
                     <id root="019e9ea5-60c1-4cb6-9af4-595d21c3a388"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Cataract Formation</title>
                     <text>
                        <paragraph>Cataract formation, including cataract cortical, cataract nuclear, cataract subcapsular, cataract traumatic, and lenticular opacities, has occurred following ENCELTO implantation [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6ccd7df0-0701-4c03-934b-03538ea16908">Adverse Reactions (6)</linkHtml>
                           </content>].  To reduce the risk of ENCELTO-related cataract formation or progression, carefully follow the specific surgical steps for ENCELTO implantation [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6f9de807-cc23-4e19-8ff0-a887b3a03c8b">Dosage and Administration (2.2)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb64cbe3e-f57c-4ba1-b88a-6d7dbcb635b1">
                     <id root="3a62d70c-decf-4f17-8377-20103d97173b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Suture Related Complications</title>
                     <text>
                        <paragraph>Suture related complications, including conjunctival erosions due to suture tips and suture knots, have occurred following ENCELTO implantation [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6ccd7df0-0701-4c03-934b-03538ea16908">Adverse Reactions (6)</linkHtml>
                           </content>].   To mitigate the risk of suture related complications, carefully follow the specific surgical steps for ENCELTO implantation [<content styleCode="italics">see  </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6f9de807-cc23-4e19-8ff0-a887b3a03c8b">Dosage and Administration (2.2)</linkHtml>
                           </content>] and manage suture-related complications as clinically indicated. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Lfef928a7-1089-440d-a5b5-7d2d27fbace1">
                     <id root="c46451ca-1b10-4c99-9119-f07b03b3f87e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Delayed Dark Adaptation</title>
                     <text>
                        <paragraph>Delayed Dark Adaptation, a delay in the ability to adjust vision from a bright lighting condition to a dim lighting, has occurred following ENCELTO administration which remained unchanged for the duration of study follow up [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6ccd7df0-0701-4c03-934b-03538ea16908">Adverse Reactions (6)</linkHtml>
                           </content>]. Advise patients to take caution while driving and navigating in the dark.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L6ccd7df0-0701-4c03-934b-03538ea16908">
               <id root="b8d75995-2c3b-41a5-b6db-d0906d345afe"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (incidence ≥2%) were conjunctival hemorrhage, delayed dark adaptation, foreign body sensation, eye pain, suture related complications, miosis, conjunctival hyperemia, eye pruritus, ocular discomfort, vitreous hemorrhage, blurred vision, headache, dry eye, eye irritation, cataract progression or formation, vitreous floaters, severe vision loss, eye discharge, anterior chamber cell, iridocyclitis. (<linkHtml href="#L9cabb892-04f5-4e66-a431-a8ee110b2674">6.1</linkHtml>)</paragraph>
                        <paragraph/>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Neurotech at 1-</content>
                           <content styleCode="bold">833-963-9275 </content>
                           <content styleCode="bold">or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">www.fda.gov/medwatch</content>
                           <content styleCode="bold">. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L9cabb892-04f5-4e66-a431-a8ee110b2674">
                     <id root="85703bd2-370b-4c6b-afc7-73201242b373"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>The safety data described in this section reflects exposure to ENCELTO in two clinical trials, Study 1 (NTMT-03-A) and Study 2 (NTMT-03-B) and are pooled for analysis. A total of 117 patients received ENCELTO, and 111 patients underwent a sham procedure and were followed for a duration of 24 months [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6dee861b-cfbd-4838-b0f9-96352d10add2">Clinical Studies (14)</linkHtml>
                           </content>]. </paragraph>
                        <paragraph>Serious adverse reactions occurred in six patients (5%) including suture related complications (n=5) and implant extrusion (n=1).  </paragraph>
                        <paragraph>
                           <linkHtml href="#table1">Table 1</linkHtml> lists the most common adverse reactions that occurred in <content styleCode="underline">&gt;</content>2% patients and with higher frequency in ENCELTO group compared to Sham group in Study 1 and Study 2.</paragraph>
                        <table ID="table1" width="100%">
                           <caption>Table 1. Adverse Reactions occurring in ≥2% of Patients and with higher frequency in ENCELTO group compared to Sham group in ENCELTO studies*</caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="middle" align="center">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reactions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>
                                       <content styleCode="bold">ENCELTO</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=117)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>
                                       <content styleCode="bold">Sham</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=111)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Conjunctival hemorrhage</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>36 (31)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>29 (26)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Delayed dark adaptation</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>27 (23.1)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>1 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Foreign body sensation in eyes</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>18 (15)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>15 (13.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Eye pain</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>18 (15)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>10 (9)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Suture related complication**</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>18 (15.4)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>3 (2.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Miosis</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>18 (15.4)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Conjunctival hyperemia</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>13 (11)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>9 (8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Eye pruritus</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>10 (9)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>4 (3.6)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Ocular discomfort</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>10 (9)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>1 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Vitreous hemorrhage</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>10 (8.5)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Vision blurred</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>8 (7)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>4 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>8 (7)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>1 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Dry eye</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>7 (6)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>2 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Eye irritation</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>6 (5.1)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>2 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Cumulative cataract incidence</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>6 (5)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>0 (0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Vitreous floaters</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>6 (5)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Severe visual loss&gt;15 letters***</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>4 (3)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>0 (0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Eye discharge</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>4 (3.4)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>1 (0.9)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Anterior chamber cell</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>4 (3.4)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph>Iridocyclitis</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>3 (2.6)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top" align="center">
                                    <paragraph>0 (0)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* Pooled data from Study 1 and Study 2; Adverse reaction rates were comparable between the two studies<br/>**Suture related complications include exposed suture, foreign body sensation, conjunctival wound dehiscence, painful sutures, suture irritation, suture granuloma, scleral wound opening, and itchy suture<br/>*** Includes one case of visual loss due to cataract formation which remained unresolved at the end of the study</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf5bac4a9-2f5e-4728-ab5c-8a4f14bf687e">
               <id root="eb5c6a36-60f2-4484-8660-fc4795831bf6"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="Ld4a4e19d-aedf-49b1-9e88-13c157470167">
                     <id root="8bc235d2-90db-451e-9ffa-0bc85516785a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>There are no data on the use of ENCELTO in pregnant women. Endogenous CNTF is naturally found in maternal plasma, placental cells, and umbilical cord blood. It is not known if the use of ENCELTO increases CNTF above naturally occurring levels in these tissues.</paragraph>
                        <paragraph/>
                        <paragraph>In animal reproduction studies, subcutaneous administration of rhCNTF to pregnant rats and rabbits demonstrated no evidence of teratogenic effects on the fetus. However, when administered to rabbits at a dose level of 10ug/kg/day, a decrease in implantations and live fetuses was observed. When administered to rats at a dose level of 100ug/kg/day a decrease in corpora lutea was observed.    </paragraph>
                        <paragraph/>
                        <paragraph>The estimated background risk of major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>See <content styleCode="italics">Risk Summary </content>for details on data<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf5ce5e3e-ac36-4ac4-af19-09424ab2f018">
                     <id root="6868916d-0567-47e0-a326-9744cf26e71a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There is no data on the presence of ENCELTO in human milk, its effects on the breastfed infant, or its impact on milk production.</paragraph>
                        <paragraph/>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ENCELTO and any potential adverse effects on the breastfed infant from rhCNTF or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L3a4fa363-2a5f-4ee8-9cb6-1138694c6377">
                     <id root="8164ead3-bc62-4f53-9bda-6d16cbfa4c1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ENCELTO have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L3fdaef36-5563-4ab5-bcae-ef924620c7ad">
                     <id root="3615ae7f-2e4e-4970-8c89-3cd9892050d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>There were 38 patients (32%) 65 years of age and older and two patients (1%) 75 years of age and older in Study 1 and Study 2 who received ENCELTO [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#L6dee861b-cfbd-4838-b0f9-96352d10add2">Clinical Studies (14)</linkHtml>
                           </content>]. Clinical studies of ENCELTO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L62a340a4-7b12-4d1f-b326-556ce66f92a2">
               <id root="6d44bb29-9b45-45e4-86c0-d0ca4f267035"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ENCELTO (revakinagene taroretcel-lwey) implant, is single-dose, sterile, nonpyrogenic and retrievable.</paragraph>
                  <paragraph/>
                  <paragraph>ENCELTO is an allogeneic encapsulated cell-based gene therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotrophic factor (rhCNTF) (NTC-201-6A cell line) for surgical intravitreal placement.</paragraph>
                  <paragraph/>
                  <paragraph>ENCELTO consists of an opaque, semi-permeable white to off-white capsule surrounding a scaffold of polyethylene terephthalate (PET) yarn, loaded with rhCNTF secreting allogeneic retinal pigment epithelial cells (NTC-201-6A cell line). Each end of the semi-permeable capsule is sealed with medical grade methacrylate adhesive, and to one end a titanium fixation loop is attached. ENCELTO width is 1.2 ± 0.1 mm, length is 6.1 ± 0.4 mm, and its internal diameter is 0.88 ± 0.02 mm (<linkHtml href="#figure17">Figure 17</linkHtml>).</paragraph>
                  <paragraph/>
                  <paragraph>ENCELTO is packaged in a protective inner container within an orange to pink liquid hold medium referred to as Endothelial Serum Free Media (Endo-SFM), which is maintained sterile by a sealed outer container. ENCELTO is provided attached, by the fixation loop, to a gripper that both suspends ENCELTO in the Endo-SFM and facilitates intraocular insertion. The Endo-SFM within the packaging inner container may contain visible particles generally described as fiber, solid, white, or metallic in appearance.</paragraph>
                  <paragraph/>
                  <paragraph>ENCELTO is manufactured using animal and human derived reagents.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="L1831662e-ce0e-4cf8-ac4d-c8f4b45ab57b">
               <id root="273d2030-0a27-415e-94cd-38e8c43e58e7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <section ID="L8b6b8136-d438-4cc6-9956-75c4f1e3078a">
                     <id root="4612ef23-b7a4-4d64-90f4-71d711afc77e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>ENCELTO secretes recombinant human ciliary neurotrophic factor (rhCNTF), which is one of several neurotrophic factors endogenously produced by neurons and supporting glial cells. Exogenous CNTF is thought to initially target Müller glia to trigger a cascade of signaling events that may promote photoreceptor survival; however, the mechanism of action for ENCELTO is not completely understood.</paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb8e731b8-2d85-4dbb-8403-28ee320ca86d">
                     <id root="00c220cf-b8c9-41c0-b701-06b2e7290f60"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Systemic exposure of rhCNTF was measured in 2 distribution studies in rabbits and in 2 toxicology studies in minipigs. Overall, there was no evidence of systemic exposure to rhCNTF after implantation of ENCELTO in rabbits for periods up to 9 months or in minipigs for periods of up to 6 months.</paragraph>
                        <paragraph>Following intraocular implantation of a single ENCELTO dose in rabbits at 12 weeks, the mean C<sub>max</sub> of rhCNTF in the vitreous and aqueous was 2.0 and 0.3 ng/mL, respectively, and below the level of quantitation (LLOQ) in the serum and contralateral, untreated eye. Similarly in human patients, rhCNTF levels were below the limit for LLOQ in the serum.</paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="L19b4e8b7-7c03-46b1-b640-4d59799ff1b8">
                     <id root="ebf02aba-a97c-420b-a00a-f376c19a3386"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.6 Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of ENCELTO or of other products.</paragraph>
                        <paragraph/>
                        <paragraph>In a six-month Study NTMT-02B in which patients received ENCELTO in a single eye, one out of 31 patients (3%) tested positive for serum antibodies against the ENCELTO secreted product protein rhCNTF and one patient (3%) tested positive to serum non-secreted intracellular protein DHFR.</paragraph>
                        <paragraph/>
                        <paragraph>Because of the low occurrence of anti-drug antibodies, the effect of serum anti-rhCNTF and anti-DHFR antibodies on the safety or efficacy of ENCELTO is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Leb9645ff-9208-498c-920d-cfda2603e44a">
               <id root="910137bb-0ff1-48d5-9679-c41a403a3d9f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="L1483d06d-c71c-4787-a0c5-6d814be348dd">
                     <id root="ee66794c-c585-43bd-b5ac-304a21cd6394"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">﻿Carcinogenesis and Mutagenesis </content>
                        </paragraph>
                        <paragraph>﻿No carcinogenicity or mutagenicity studies have been conducted with rhCNTF. </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">﻿Impairment of Fertility</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>In male rats, fertility was unaffected at subcutaneous doses of rhCNTF up to 300 μg/kg/day. </paragraph>
                        <paragraph/>
                        <paragraph>See <content styleCode="italics">
                              <linkHtml href="#Ld4a4e19d-aedf-49b1-9e88-13c157470167">Pregnancy (8.1)</linkHtml>
                           </content> for data regarding effects on female fertility. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L6dee861b-cfbd-4838-b0f9-96352d10add2">
               <id root="97c534fa-ed94-4d1f-929c-2842c7fec6ff"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph styleCode="First Text1">The efficacy of ENCELTO was evaluated in two studies, Study NTMT-03-A (<linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT03316300">NCT03316300</linkHtml>; Study 1) and Study NTMT-03-B (<linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT03319849">NCT03319849</linkHtml>; Study 2) as described below.</paragraph>
                  <paragraph/>
                  <paragraph styleCode="Text1">
                     <content styleCode="italics">
                        <content styleCode="underline">Study 1</content>
                     </content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Study 1 was a randomized, multi-center, sham-controlled study which enrolled adults with MacTel. For enrollment, the patients were required to have a photoreceptor inner segment/outer segment (IS/OS PR) break (loss) in ellipsoid zone (EZ) between 0.16 and 2.00 mm<sup>2 </sup>measured by spectral domain-optical coherence tomography (SD-OCT) and best corrected visual acuity (BCVA) of 54-letter score or better (20/80 or better) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at screening. Patients with neovascular MacTel were excluded. Patients were randomized to receive either ENCELTO intravitreal implant or sham procedure under standard operative procedures. Patients in ENCELTO group underwent conjunctival peritomy, implant placement in the vitreous cavity via sclerotomy and closure with sutures. Patients in the Sham group underwent conjunctival peritomy, scleral pressure, and conjunctival closure with sutures.  One hundred and fifteen (96%) of 120 patients underwent the assigned procedure and were included in the analysis of efficacy.</paragraph>
                  <paragraph/>
                  <paragraph styleCode="Text1">A total of 120 patients were randomized and of these, 115 patients (ENCELTO group: 58; Sham group: 57) comprise the efficacy analysis population. The demographic characteristics of the efficacy analysis population were as follows: the mean age was 61 years (range 40 to 78 years), 79 patients (69%) were female, 98 patients (85%) were White, 5 patients (4%) were Asian, 3 patients (3%) were Black or African American, 1 patient (1%) was American Indian, and 8 patients (7%) were of “other” race. Six patients (5%) were Hispanic. The median (min, max) baseline EZ area loss was 0.35 (0.15, 1.99) mm<sup>2</sup> for the ENCELTO group and 0.36 (0.16, 1.7) mm<sup>2 </sup>for the Sham group. The median (min, max) baseline aggregate sensitivity of microperimetry within the EZ break area 35.2 (0.75, 398.8) dB for the ENCELTO group and 35.5 (2, 281.3) dB for the Sham group.</paragraph>
                  <paragraph styleCode="Text1"/>
                  <paragraph styleCode="Text1">The primary efficacy outcome measure was the rate of change in the area of EZ loss (IS/OS, macular PR loss) over 24 months, as measured by SD-OCT. The secondary outcome measure was the mean change in aggregate sensitivity loss of microperimetry within the EZ break area from baseline to Month 24.</paragraph>
                  <paragraph/>
                  <paragraph styleCode="Normal-text">The efficacy outcome results for Study 1 are summarized in <linkHtml href="#table2">Table 2</linkHtml>.</paragraph>
                  <table ID="table2">
                     <caption>Table 2. Efficacy Results for Study 1 (N=115)</caption>
                     <thead>
                        <tr styleCode="First Last">
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Efficacy endpoints</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">ENCELTO</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">n= 58</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Sham</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">n=57</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Difference</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">ENCELTO-Sham</content>
                              </paragraph>
                              <paragraph/>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">P-value<sup>c</sup>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="left">
                              <paragraph>Rate of change in EZ area loss from baseline over 24 months<sup>a</sup>
                              </paragraph>
                              <paragraph>mm<sup>2</sup>
                              </paragraph>
                              <paragraph>(95% CI)</paragraph>
                              <paragraph/>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>0.075</paragraph>
                              <paragraph>(0.05, 0.10)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>0.166</paragraph>
                              <paragraph>(0.14, 0.19)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>-0.091</paragraph>
                              <paragraph>(-0.13, -0.06)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>&lt;0.0001</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="left">
                              <paragraph>Mean change in aggregate retinal sensitivity loss from baseline to 24-months<sup>b</sup>
                              </paragraph>
                              <paragraph>dB</paragraph>
                              <paragraph>(95% CI)</paragraph>
                              <paragraph/>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>25.27</paragraph>
                              <paragraph>(15.88, 34.67)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>43.02</paragraph>
                              <paragraph>(31.78, 54.26)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>-17.75</paragraph>
                              <paragraph>(-32.58, -2.91)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph>0.02</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph styleCode="Text1">CI = confidence interval, EZ=ellipsoid zone</paragraph>
                  <paragraph styleCode="Text1">
                     <sup>a</sup> Estimated by using a longitudinal mixed model including EZ area loss as the dependent variable, patient-specific random intercepts, treatment group, time (continuous), and interaction between treatment and time as covariates. The baseline and Months 12, 16, 20, and 24 visits were included.</paragraph>
                  <paragraph styleCode="Text1">
                     <sup>b</sup> Estimated by using two-sample t-test; seven ENCELTO and four Sham patients were excluded due to missing data.</paragraph>
                  <paragraph styleCode="Text1">
                     <sup>c</sup> Statistically significant at two-sided alpha of 0.05.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph styleCode="Text1"/>
                  <paragraph styleCode="Text1"/>
                  <paragraph styleCode="Text1">
                     <content styleCode="italics">
                        <content styleCode="underline">Study 2</content>
                     </content>
                  </paragraph>
                  <paragraph/>
                  <paragraph styleCode="Text1">Study 2 was a randomized, multi-center, sham-controlled study which enrolled adult with MacTel. For enrollment, the patients were required to have an IS/OS PR break in EZ between 0.16 and 2.00 mm<sup>2 </sup>measured by SD-OCT and BCVA of 54-letter score or better (20/80 or better) as measured by the ETDRS chart at screening. Patients with neovascular MacTel were excluded.</paragraph>
                  <paragraph styleCode="Text1">Patients were randomized to receive either ENCELTO intravitreal implant or sham procedure under standard peri-operative procedures. Patients in ENCELTO group underwent conjunctival peritomy, implant placement in the vitreous cavity via sclerotomy and closure with sutures. Patients in the Sham group underwent conjunctival peritomy, scleral pressure, and conjunctival closure with sutures. One hundred and thirteen (95%) of the 119 patients underwent the assigned procedure and were included in efficacy evaluation.</paragraph>
                  <paragraph/>
                  <paragraph styleCode="Normal-text">A total of 119 patients were randomized and of these, 113 patients (ENCELTO group: 59; Sham group: 54) comprise the efficacy analysis population. The demographic characteristics of the efficacy analysis population were as follows: the mean age was 59 years (range: 40 to 75 years), 82 patients (73%) were female, 102 patients (90%) were White, 4 patients (4%) were Asian, and 7 patients (6%) were of “other” race or “unable to specify” race. Eight patients (7%) were Hispanic. The median (min, max) baseline EZ area loss was 0.48 (0.16, 1.63) mm<sup>2</sup> for the ENCELTO and 0.39 (0.16, 1.38) mm<sup>2 </sup>for the Sham group. The median (min, max) baseline aggregate sensitivity of microperimetry within the EZ break area 40.07 (4.82, 291.52) dB for the ENCELTO group and 28.86 (0.33, 221.17) dB for the Sham group.</paragraph>
                  <paragraph styleCode="Normal-text"/>
                  <paragraph styleCode="Normal-text">The primary efficacy outcome measure was the rate of change in the area of EZ loss (IS/OS, macular PR loss) over 24 months, as measured by SD-OCT. The secondary outcome measure was the mean change in aggregate sensitivity loss of microperimetry within the EZ break area from baseline to Month 24.</paragraph>
                  <paragraph/>
                  <paragraph styleCode="Normal-text">The efficacy results from Study 2 are summarized in <linkHtml href="#table3">Table 3</linkHtml> below.</paragraph>
                  <table ID="table3">
                     <caption>Table 3. Efficacy Results for Study 2 (N=113)</caption>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Efficacy endpoints</content>
                              </paragraph>
                              <paragraph/>
                              <paragraph/>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">ENCELTO</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">n= 59</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Sham</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">n=54</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Difference</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">ENCELTO-Sham</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">P-value<sup>c</sup>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" valign="top">
                              <paragraph>Rate of change in EZ area loss from baseline over 24 months<sup>a</sup>
                              </paragraph>
                              <paragraph>mm<sup>2</sup>
                              </paragraph>
                              <paragraph>(95% CI)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>0.111</paragraph>
                              <paragraph>(0.08, 0.14)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>0.160</paragraph>
                              <paragraph>(0.13, 0.19)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>-0.049</paragraph>
                              <paragraph>(-0.089, -0.008)</paragraph>
                              <paragraph/>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>0.0186<sup>c</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>Mean change in aggregate retinal sensitivity loss from baseline to 24-month<sup>b</sup>
                              </paragraph>
                              <paragraph>dB</paragraph>
                              <paragraph>(95% CI)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>40.02</paragraph>
                              <paragraph>(26.08, 53.96)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>41.97</paragraph>
                              <paragraph>(30.34, 53.60)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph/>
                              <paragraph>-1.95</paragraph>
                              <paragraph>(-20.33, 16.43)</paragraph>
                              <paragraph/>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                              <paragraph/>
                              <paragraph>0.83</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>CI = confidence interval, EZ=ellipsoid zone</paragraph>
                  <paragraph>
                     <sup>a</sup> Estimated by using a longitudinal mixed model including EZ area loss as the dependent variable, patient-specific random intercepts, treatment group, time (continuous), and interaction between treatment and time as covariates. The baseline and Months 12, 16, 20, and 24 visits were included.</paragraph>
                  <paragraph>
                     <sup>b</sup> Estimated by using two-sample t-test; Seven ENCELTO and six Sham patients were excluded due to missing data.</paragraph>
                  <paragraph>
                     <sup>c</sup> Statistically significant at two-sided alpha of 0.05.</paragraph>
               </text>
               <effectiveTime value="20250317"/>
            </section>
         </component>
         <component>
            <section ID="L25e2aaa1-dc19-4856-9ae0-43ec26e5d505">
               <id root="7a94581b-2d65-466c-8b32-1a5bde86595b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <section ID="L887fcee9-11b0-48bb-8554-e0fdc0800379">
                     <id root="54d481db-8782-4c47-9603-693511d216e2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>ENCELTO is supplied as a sterile, single-dose, implant that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing rhCNTF (NTC-201-6A cell line).</paragraph>
                        <paragraph>ENCELTO is packaged in a protective inner container within an Endothelial Serum Free Media (Endo-SFM), which is maintained sterile by a sealed outer container. ENCELTO is provided attached to a gripper that both suspends ENCELTO in the Endo-SFM and facilitates intraocular insertion. ENCELTO contains no preservatives.</paragraph>
                        <paragraph>NDC: 82958-501-01</paragraph>
                        <paragraph>See <linkHtml href="#table4">Table 4</linkHtml>, (<linkHtml href="#figure16">Figure 16</linkHtml>) and ENCELTO “Instructions for Use” for additional details.</paragraph>
                        <table ID="table4">
                           <caption>Table 4. ENCELTO Corepack Contents</caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Components</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Description</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">Inner container</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">This is provided sterile. It is a cylindrical plastic container with a lower compartment filled with liquid medium. It has an upper compartment connected to it via a narrow channel that is secured shut with a luer lock cap.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">Outer container</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">This is a plastic container with a foil lid hermetically sealed. It maintains the sterility of the inner container until ready to use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">Disposable temperature recording device</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">A disposable device that measures and records the temperature in the package. If ENCELTO has been stored within the acceptable range, a “✓” will be shown at the top of the screen. If an “X” is displayed, ENCELTO has been exposed to temperatures outside of the acceptable range and must not be used.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">ENCELTO Medium pH Color Guide</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">A card that provides a color scale to indicate the acceptable pH range for the liquid medium.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">ENCELTO Instructions for Use</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">A booklet that contains the full instructions and includes the ENCELTO patient card.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">ENCELTO Inspection Checklist</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">An information sheet that contains instructions for inspection prior to use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">USPI</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <paragraph styleCode="Default First">United States Prescribing Information.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 16. ENCELTO Corepack Contents</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="Lbf67b116-a79f-47fb-99d0-1ea5d0730873" ID="figure16"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 17. ENCELTO</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="L5617896e-9502-4140-ae7c-a3261b1aa342" ID="figure17"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 18. ENCELTO Inner Container</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="L3bf1214e-b89a-42af-9622-ad39d9e01b15" ID="figure18"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 19. pH Color Guide</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="L905fc538-f011-49b4-b5ce-0604b2382c14" ID="figure19"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                     <component>
                        <observationMedia ID="Lbf67b116-a79f-47fb-99d0-1ea5d0730873">
                           <text>image description</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-16.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L5617896e-9502-4140-ae7c-a3261b1aa342">
                           <text>image description</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-17.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L3bf1214e-b89a-42af-9622-ad39d9e01b15">
                           <text>image description</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-18.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L905fc538-f011-49b4-b5ce-0604b2382c14">
                           <text>image description</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="encelto-figure-19.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Le095dc31-3171-47cf-af64-300575be22d3">
                     <id root="84b1de40-968a-44ca-8942-699ff04fdc29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph styleCode="First Text1">1. Using the handle, remove the corepack from the larger shipping box (<linkHtml href="#figure16">Figure 16</linkHtml>). </paragraph>
                        <paragraph styleCode="Text1">2. Store ENCELTO in the corepack at 16º to 37ºC (61º to 99ºF) until ready for use. </paragraph>
                        <paragraph styleCode="Text1">3. Do not freeze or refrigerate.  </paragraph>
                        <paragraph styleCode="Text1">4. Inspect the disposable temperature recording device. If a check mark is displayed, the ENCELTO has remained within the acceptable temperature range and may be used. If a “X” is displayed, the ENCELTO was exposed to temperatures outside the acceptable range and must not be used.  Contact Neurotech immediately at (833)-963-9275.</paragraph>
                        <paragraph styleCode="Text1">   • Protect ENCELTO from light. </paragraph>
                        <paragraph styleCode="Text1">5. Handle inner container (<linkHtml href="#figure18">Figure 18</linkHtml>) using sterile technique.</paragraph>
                        <paragraph styleCode="Text1">6. Do not use beyond the “use by” date identified on the corepack label. </paragraph>
                        <paragraph styleCode="Text1">7. Do not use ENCELTO if the pH is not within the acceptable range (<linkHtml href="#figure19">Figure 19</linkHtml>). Contact Neurotech immediately at (833)-963-9275.</paragraph>
                        <paragraph styleCode="Text1">   • Prior to disposal of an ENCELTO implant per local institutional protocols, call 1-833-963-9275 for assessment of ENCELTO return or replacement.</paragraph>
                        <paragraph styleCode="Text1"/>
                        <paragraph styleCode="Text1">Orange to pink liquid hold medium referred to as Endothelial Serum Free Media (Endo-SFM) within packaging inner container may contain visible particles. Particle general description fiber, solid, white, or metallic in appearance. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lb893cd32-f4f2-457b-8aba-7e373e5d4c00">
               <id root="c6c68ae4-d87a-4d64-9b18-edf729648979"/>
               <code code="88436-1" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT COUNSELING INFORMATION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph/>
                  <paragraph>Discuss the following with the patient.</paragraph>
                  <paragraph/>
                  <paragraph>Advise patients that ENCELTO implantation may be associated with  infectious endophthalmitis (eye infection), retinal tear and detachment (retina separates from the eye wall resulting in vision loss), vitreous hemorrhage (bleeding within the central cavity of the eye), implant extrusion, suture-related complications, cataract formation (clouding of the lens of the eye), severe vision loss, and delayed dark adaptation (ability of the eye to adjust from bright lighting conditions to dark lighting conditions) [<content styleCode="italics">see <linkHtml href="#L45999af3-0a1e-4eaa-a6ae-f5af7425dc82">Warnings and Precautions (5)</linkHtml>
                     </content>].</paragraph>
                  <paragraph/>
                  <paragraph>Instruct patients to seek immediate care from an ophthalmologist if they experience any signs or symptoms that could be associated with these events which may include the following:</paragraph>
                  <paragraph/>
                  <list listType="unordered">
                     <item>An increase in floaters, the appearance of “spider webs”, flashing lights, sensitivity to light, or loss of vision or visual field;</item>
                     <item>Increasing eye pain, progressive redness in the white of the eye, a sudden sensation that something is in their eye (i.e., foreign body sensation) or eye discharge.</item>
                  </list>
                  <paragraph/>
                  <paragraph>Advise patients that they may temporarily experience the following after ENCELTO implantation:</paragraph>
                  <paragraph/>
                  <list listType="unordered">
                     <item>Mild sensation of something in the eye (i.e., foreign body sensation)</item>
                     <item>Eye redness, irritation, pain or discomfort, or dryness</item>
                     <item>Blurred vision or floaters</item>
                  </list>
                  <paragraph/>
                  <paragraph>Advise patients that delayed dark adaptation may be experienced for the length of time that ENCELTO is surgically placed [<content styleCode="italics">see <linkHtml href="#Lfef928a7-1089-440d-a5b5-7d2d27fbace1">Warnings and Precautions (5.8)</linkHtml>
                     </content>].  Advise patients on the following safety precautions. </paragraph>
                  <list listType="unordered">
                     <item>Driving: delayed dark adaptation may impair one's ability to see objects, pedestrians, or road signs when moving rapidly from a brightly lit environment to a dimly lit environment (for example, entering a tunnel during the daytime).</item>
                     <item>Navigating in the dark: Advise caution when moving from bright to dark areas, such as entering a dark room or stepping outside at dusk. Consider using flashlights, nightlights, or motion-activated lighting at home.</item>
                     <item>Consider wearing sunglasses or tinted lenses in bright environments to reduce the impact of transitioning from light to dark.</item>
                  </list>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="underline">Magnetic Resonance (MR) Conditional Information</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Leb4b97f6-c6c1-468e-bd4c-e31fc84df353"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>ENCELTO is MR conditional. Advise patients that they have ENCELTO implanted in their eye and provide the patient with their implant card should they require Magnetic Resonance Imaging (MRI).</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="underline">Driving and Using Machines</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Advise patients to not drive or use machinery until the eye shield has been removed and their ophthalmologist informs them that their vision has recovered to an acceptable level.</item>
                  </list>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="underline">Postoperative Care</content>
                  </paragraph>
                  <paragraph>Advise patients on the following post operative care:</paragraph>
                  <list listType="unordered">
                     <item>Avoid heavy lifting (over 20 pounds) for one week.</item>
                     <item>Keep water out of the eye (e.g., close eye while showering) for one week.</item>
                     <item>Protect eyes by wearing glasses or protective eyewear during the day and using an eye shield at night for one week.</item>
                     <item>Use a topical antibiotic solution at a frequency of 1 drop four times a day for 7 days.</item>
                     <item>Use a steroid drop taper of prednisolone acetate 1% (or equivalent) starting the day after surgery with the following taper:<list listType="unordered">
                           <item>1 drop four times a day for the first 7 days;</item>
                           <item>1 drop three times a day for the next 7 days;</item>
                           <item>1 drop two times a day for the next 7 days;</item>
                           <item>1 drop once a day for the last 7 days.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph/>
                  <paragraph styleCode="Indent-2">Manufactured by:</paragraph>
                  <paragraph>Neurotech Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Building 1, Suite 101</paragraph>
                  <paragraph>Cumberland, RI 02864</paragraph>
                  <paragraph/>
                  <paragraph>U.S. license number: 2321</paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="Leb4b97f6-c6c1-468e-bd4c-e31fc84df353">
                     <text>MR Conditional Info</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="mr-conditional.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="La3ae523e-452a-42f6-a89d-d44196ddce70">
               <id root="1389b6c9-e8ab-4273-9155-f9429c8c2f82"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table border="1" cellspacing="0" cellpadding="0">
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="center">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                              </paragraph>
                              <paragraph styleCode="TableParagraph">
                                 <content styleCode="bold">ENCELTO (En-SEL-toh) </content>
                              </paragraph>
                              <paragraph styleCode="TableParagraph">
                                 <content styleCode="bold">A surgical implant for use in the eye</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="left">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">What is ENCELTO?</content>
                              </paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">ENCELTO is an encapsulated cell-based gene therapy. It is a small capsule, about the size of a grain of rice, that is placed inside the eye to release a protein called recombinant human ciliary neurotrophic factor (rhCNTF) that can directly reach the retina, the light sensitive part of the eye. The capsule contains living cells that have been genetically modified to continuously produce and release CNTF. This protein helps protect certain cells in your retina, supporting their health and reducing the loss of light-sensing cells known as photoreceptors.</paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">ENCELTO is used to treat adults with idiopathic macular telangiectasia type 2 (MacTel); a retinal disease that causes progressive vision loss. Your ophthalmologist will assess your vision and review your medical history to determine if ENCELTO is the right treatment for you.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="left">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">Who should not receive an ENCELTO surgical implant?</content>
                              </paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">ENCELTO has not been tested in pediatric patients or pregnant women.</paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">The outpatient surgical procedure should not be performed if you are currently experiencing an active or suspected eye infection.</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">You should not receive ENCELTO if you have a known hypersensitivity to Endothelial Serum Free Media (Endo-SFM)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">Before receiving ENCELTO, tell your ophthalmologist about all your medical conditions, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Are pregnant or plan to become pregnant. Although studies have shown that rhCNTF does not enter the bloodstream, its effects on an unborn baby have not been fully studied.</item>
                                 <item>Are breastfeeding or plan to breastfeed. It is not known if rhCNTF passes into your breast milk.</item>
                                 <item>Any current infections</item>
                                 <item>Are currently taking or have recently taken medicines that lower the chance of blood clots forming in the body such as warfarin, low or regular doses of aspirin, or nonsteroidal anti-inflammatory drugs (NSAID)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="left">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">How is ENCELTO administered?</content>
                              </paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">ENCELTO is inserted into the eye as an outpatient surgical procedure performed by an ophthalmologist experienced in retinal surgery. If removal of ENCELTO is necessary, the removal surgery must also be done by an ophthalmologist experienced in vitreoretinal surgery in an operating room as an outpatient surgery.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="left">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">What should I avoid after placement of ENCELTO?</content>
                              </paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">Immediately post-operative:</paragraph>
                              <list listType="unordered">
                                 <item>Avoid heavy lifting (over 20 pounds) for one week.</item>
                                 <item>Keep water out of the eye (e.g., close your eye while showering) for one week.</item>
                                 <item>Protect your eyes by wearing glasses or protective eyewear during the day and using an eye shield at night for one week.</item>
                                 <item>Do not drive or use machinery until the eye shield has been removed and your ophthalmologist informs you that your vision has recovered to an acceptable level.</item>
                              </list>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">Post operative care:</paragraph>
                              <list listType="unordered">
                                 <item>Use a topical antibiotic solution at a frequency of 1 drop four times a day for 7 days.</item>
                                 <item>Use a steroid drop taper of prednisolone acetate 1% (or equivalent) starting the day after surgery with the following taper:<list listType="unordered">
                                       <item>1 drop four times a day for the first 7 days;</item>
                                       <item>1 drop three times a day for the next 7 days;</item>
                                       <item>1 drop two times a day for the next 7 days;</item>
                                       <item>1 drop once a day for the last 7 days.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph styleCode="TableParagraph">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Magnetic Resonance (MR) Conditional Information</content>
                                 </content>
                              </paragraph>
                              <paragraph styleCode="TableParagraph">
                                 <renderMultiMedia referencedObject="L7290c06e-7444-4f2b-8e66-937973fd0476"/>
                              </paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph">
                                 <content styleCode="bold">IMPORTANT: ENCELTO is MR conditional. </content>You will receive an implant card, which should be shown to your imaging technician if you need Magnetic Resonance Imaging (MRI) at any time while the ENCELTO implant is in your eye. The card will include details about the ENCELTO implant, the date of insertion, and on the back, instructions for the imaging technician to access important MRI safety information.</paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph">Call your ophthalmologist for medical advice about side effects. You may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088.</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="left">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">What are the possible side effects of ENCELTO?</content>
                              </paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">Please follow all post-operative instructions given by your ophthalmologist and ensure you attend all follow-up visits as recommended.</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Potential side effects</content>
                                 </content>
                              </paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">Please be advised that ENCELTO and the surgical insertion has related risks such as, but not limited to, endophthalmitis (eye infection), retinal tear and detachment (retina tears and potentially separates from the eye wall resulting in vision loss), vitreous hemorrhage (bleeding within the central cavity of the eye), implant extrusion (the ENCELTO begins to work it’s way out of the eye), suture related issues (such as suture related eye irritation or exposure of sutures), temporary or permanent loss of vision, accelerated cataract formation (clouding of the lens of the eye), and delayed dark adaptation (the ability of the eye to adjust from bright lighting conditions to dark lighting conditions).</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">If delayed dark adaptation occurs, it is unknown for how long these symptoms will be experienced. Take the following safety precautions.</paragraph>
                              <list listType="unordered">
                                 <item>Driving: delayed dark adaptation may impair one's ability to see objects, pedestrians, or road signs when moving rapidly from a brightly lit environment to a dimly lit environment (for example, entering a tunnel during the daytime).</item>
                                 <item>Navigating in the Dark: Take caution when moving from bright to dark areas, such as entering a dark room or stepping outside at dusk. Consider using flashlights, nightlights, or motion-activated lighting at home.</item>
                                 <item>Consider wearing sunglasses or tinted lenses in bright environments to reduce the impact of transitioning from light to dark</item>
                              </list>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">It is common to experience the following symptoms following ENCELTO surgery:</paragraph>
                              <list listType="unordered">
                                 <item>Sensation of something in the eye (i.e., foreign body sensation)</item>
                                 <item>Eye redness</item>
                                 <item>Eye irritation</item>
                                 <item>Eye dryness</item>
                                 <item>Eye discharge</item>
                                 <item>Mild to moderate eye pain or discomfort</item>
                                 <item>Floaters (small spots or shapes that appear in your vision)</item>
                                 <item>Headache</item>
                              </list>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">
                                 <content styleCode="bold">
                                    <content styleCode="underline">When to Seek Ophthalmologist Advice</content>
                                 </content>
                              </paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph">You are to seek immediate care from an ophthalmologist if there are sudden changes in your vision, such as an increase in floaters, the appearance of “spider webs,” flashing lights, sensitivity to light, loss of vision or visual field, progressively worsening eye pain, or increasing discharge/drainage from the eye as these symptoms could be a sign of a more serious issue.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="left">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">General information about the safe and effective use of ENCELTO</content>
                              </paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">You can ask your ophthalmologist for a copy of the information about ENCELTO that is written for healthcare professionals.</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <br/>
                              <paragraph styleCode="TableParagraph">You should inform your ophthalmologist that you have an ENCELTO implant inserted prior to any eye examination.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule TopRule" colspan="1" align="left">
                              <paragraph styleCode="First TableParagraph">
                                 <content styleCode="bold">What are the ingredients in ENCELTO?</content>
                              </paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">Active ingredients: ENCELTO is an encapsulated cell-based therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing rhCNTF (NTC-201-6A cell line), a neurotrophic factor.</paragraph>
                              <br/>
                              <paragraph styleCode="TableParagraph">Inactive ingredients: ENCELTO contains excipients (Human Endothelial Serum Free Medium (SFM) that may cause sensitivity in some patients.</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">
                                 <br/>
                                 <content styleCode="bold">Manufactured for: </content>Treatment of idiopathic macular telangiectasia type 2 (MacTel)</paragraph>
                              <paragraph styleCode="TableParagraph"/>
                              <paragraph styleCode="TableParagraph">
                                 <br/>
                                 <content styleCode="bold">Manufactured by:</content>
                              </paragraph>
                              <paragraph styleCode="TableParagraph">Neurotech Pharmaceuticals, Inc.</paragraph>
                              <paragraph styleCode="TableParagraph">Building 1, Suite 101</paragraph>
                              <paragraph styleCode="TableParagraph">Cumberland, Rhode Island, 02864</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.                                                             F11002F Rev. 01<br/>Revised: 2025/03</paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="L7290c06e-7444-4f2b-8e66-937973fd0476">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="mr-conditional-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L3690735f-65d2-46e5-92c4-0cfe5709a73d">
               <id root="e280e5e3-d7ac-4a84-81d1-b76221a84187"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use </title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="L60dcf49a-9707-4b07-9d52-2e2d4292b390"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L8cd624fc-a63c-4b79-ba8f-f891b913c2d4"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L325b4814-884f-42b0-b2d5-b4f6321fb790"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="La482e757-717f-444f-b8ee-5e4948ab913e"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L51006e78-5d1d-4ea7-b0b8-5a9a57990e39"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L60ec8bd2-6241-4cae-8bb3-f3552f08d91b"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lffae1103-b04d-4ce6-9786-9ab6f36eeb02"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Le1d92526-1305-4b93-8b65-9139281ff8b3"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L530e13c6-c2e6-4347-a690-77160e6fb345"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L032f795e-61c1-471d-a466-5f3b7e0a44be"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ldc863b53-97ca-41ec-99ca-b4cf6d77cbc2"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lb834d399-b41e-4fdb-ab39-1754495a9885"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ld91a0a27-b896-470b-8a21-68c6ac341b33"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ld98479ea-f3ca-4381-b95a-4a98b7b2ccb5"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L3936294e-a4d7-4744-9693-0a4fb5944247"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L0e70aab0-29d0-48ba-9c89-05d531e9d236"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L314fdd50-1ee8-4e86-804a-e10ec73bd527"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L973d8608-c7c3-4fde-9302-e12fb580ca2e"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="La9c83204-0bb0-4910-b8af-1fa60cd15969"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lee5da909-07c5-41fe-8b7a-de6fafb4a32c"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L022a0d7f-4c2a-4532-bcd3-afbd083e05db"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L3c4bf2e0-29b6-48e2-8a85-0a03846e615e"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L545935d2-1cdf-402c-b01b-376de0c94790"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L2a9e00fc-2e0b-49ec-9819-157eb846c431"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L9594e7d3-1c63-4efd-9808-038efe95ab13"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L63c8c3ff-c698-4505-a839-ec4738e6fff7"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L1420b213-530b-40b7-b2a9-6f16d7b09bb4"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lee5dd590-47a7-423c-be9b-3c0508c0f90f"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L79e99058-a566-478a-aaec-f1c4ca051561"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L462ffada-f4e9-4ac1-a422-5a2e3317b0a3"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lab8724e2-0df5-4d1b-992d-1b186e5cdc90"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="La1338213-8934-4d81-9012-a89d91942465"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L0a59ffc6-9b2d-47a0-91a2-c794e54fe854"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L9724086c-9e5c-4f24-aed0-42faf34fdda9"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L4386bfc4-5e26-4848-aeae-f0d03f000104"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ld4625488-46b3-4c83-90cc-bf92accbf4d3"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L96bd4942-a062-45b9-89a6-2325be07ce64"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L51a02c2b-7b1d-461a-b20b-e0eba913f302"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L8ffacb42-0dca-4e84-a77f-b048a5eb1e19"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L763dda74-35a6-453e-a393-f3d52609cc0c"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lcdd68d23-f7bc-4902-9130-dfb08eec91ff"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L3a7493dd-29f8-4a2d-8109-46009112bc6f"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lcfc6b861-257a-44a2-b7a4-08f2b9dd2719"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L5c0a5473-46fa-43c3-95b9-a68c56c79fa1"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lb2caec41-97fa-4155-8063-a8db460118bc"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L62e5ea35-f6b7-4741-bae1-9ebc0fd2de3d"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L87da1f19-1bc2-45ce-97cf-922355a911b9"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L750cd46a-fd96-4111-8dd8-816e09da08b0"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L89e40bbb-5875-4466-bf5a-92204ee74ead"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L6daf72d2-75a8-46a3-a29e-73834fa4ee28"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L6ea5b3ae-1711-4498-89e3-9e358a78748f"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L93393b62-2ce5-4600-84cf-6c5a7a3f6df0"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="L60dcf49a-9707-4b07-9d52-2e2d4292b390">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L8cd624fc-a63c-4b79-ba8f-f891b913c2d4">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L325b4814-884f-42b0-b2d5-b4f6321fb790">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="La482e757-717f-444f-b8ee-5e4948ab913e">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L51006e78-5d1d-4ea7-b0b8-5a9a57990e39">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L60ec8bd2-6241-4cae-8bb3-f3552f08d91b">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lffae1103-b04d-4ce6-9786-9ab6f36eeb02">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Le1d92526-1305-4b93-8b65-9139281ff8b3">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L530e13c6-c2e6-4347-a690-77160e6fb345">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L032f795e-61c1-471d-a466-5f3b7e0a44be">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Ldc863b53-97ca-41ec-99ca-b4cf6d77cbc2">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lb834d399-b41e-4fdb-ab39-1754495a9885">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Ld91a0a27-b896-470b-8a21-68c6ac341b33">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Ld98479ea-f3ca-4381-b95a-4a98b7b2ccb5">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L3936294e-a4d7-4744-9693-0a4fb5944247">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L0e70aab0-29d0-48ba-9c89-05d531e9d236">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L314fdd50-1ee8-4e86-804a-e10ec73bd527">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L973d8608-c7c3-4fde-9302-e12fb580ca2e">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="La9c83204-0bb0-4910-b8af-1fa60cd15969">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lee5da909-07c5-41fe-8b7a-de6fafb4a32c">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L022a0d7f-4c2a-4532-bcd3-afbd083e05db">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L3c4bf2e0-29b6-48e2-8a85-0a03846e615e">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L545935d2-1cdf-402c-b01b-376de0c94790">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L2a9e00fc-2e0b-49ec-9819-157eb846c431">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L9594e7d3-1c63-4efd-9808-038efe95ab13">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L63c8c3ff-c698-4505-a839-ec4738e6fff7">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L1420b213-530b-40b7-b2a9-6f16d7b09bb4">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lee5dd590-47a7-423c-be9b-3c0508c0f90f">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L79e99058-a566-478a-aaec-f1c4ca051561">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L462ffada-f4e9-4ac1-a422-5a2e3317b0a3">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lab8724e2-0df5-4d1b-992d-1b186e5cdc90">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="La1338213-8934-4d81-9012-a89d91942465">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-32.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L0a59ffc6-9b2d-47a0-91a2-c794e54fe854">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-33.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L9724086c-9e5c-4f24-aed0-42faf34fdda9">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-34.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L4386bfc4-5e26-4848-aeae-f0d03f000104">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-35.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Ld4625488-46b3-4c83-90cc-bf92accbf4d3">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-36.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L96bd4942-a062-45b9-89a6-2325be07ce64">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-37.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L51a02c2b-7b1d-461a-b20b-e0eba913f302">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-38.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L8ffacb42-0dca-4e84-a77f-b048a5eb1e19">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-39.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L763dda74-35a6-453e-a393-f3d52609cc0c">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-40.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lcdd68d23-f7bc-4902-9130-dfb08eec91ff">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-41.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L3a7493dd-29f8-4a2d-8109-46009112bc6f">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-42.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lcfc6b861-257a-44a2-b7a4-08f2b9dd2719">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-43.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L5c0a5473-46fa-43c3-95b9-a68c56c79fa1">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-44.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lb2caec41-97fa-4155-8063-a8db460118bc">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-45.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L62e5ea35-f6b7-4741-bae1-9ebc0fd2de3d">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-46.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L87da1f19-1bc2-45ce-97cf-922355a911b9">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-47.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L750cd46a-fd96-4111-8dd8-816e09da08b0">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-48.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L89e40bbb-5875-4466-bf5a-92204ee74ead">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-49.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L6daf72d2-75a8-46a3-a29e-73834fa4ee28">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-50.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L6ea5b3ae-1711-4498-89e3-9e358a78748f">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-51.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L93393b62-2ce5-4600-84cf-6c5a7a3f6df0">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-ifu-52.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L90689e08-35b3-4cc4-8b36-d9165425a45f">
               <id root="322f52b9-f0e2-44c8-aeda-917735803f25"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>ENCELTO PRODUCT LABEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="L56cb4fdf-a798-4f92-a79a-874138e4e43d"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="L56cb4fdf-a798-4f92-a79a-874138e4e43d">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-product-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L61e45b2f-420c-44b8-98a7-0f9d47c2afc5">
               <id root="5f99f099-5164-4903-b2ad-92c459b4db98"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>ENCELTO COREPACK LABEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="L2617b9d2-cd4f-4cc7-b3bf-4d00187d1b8a"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="L2617b9d2-cd4f-4cc7-b3bf-4d00187d1b8a">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="encelto-corepack-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>